✦ LIBER ✦

Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma

✍ Scribed by Dimitrios Pectasides; Nicolaos Xiros; George Papaxoinis; Gerasimos Aravantinos; Constantinos Sykiotis; Erini Pectasides; Amanda Psyrri; Anna Koumarianou; Asimina Gaglia; Panayiotis Gouveris; Theofanis Economopoulos

Book ID: 113961320
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 182 KB
Volume: 108
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2007.08.061

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Carboplatin/gemcitabine alternating with

Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel — pretreated ovarian carcinoma

✍ D. Pectasides; E. Pectasides; G. Papaxoinis; A. Psyrri; K. Pliarchopoulou; A. Ko 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 234 KB

Biweekly gemcitabine and cisplatin in pl

Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma

✍ George Bozas; Aristotle Bamias; Vassiliki Koutsoukou; Eleni Efstathiou; Dimitra 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 227 KB

Phase 2 study of canfosfamide in combina

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

✍ John J Kavanagh; Charles F Levenback; Pedro T Ramirez; Judith L Wolf; Carla L Mo 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 404 KB

926 POSTER Phase II austrian AGO study o

926 POSTER Phase II austrian AGO study of pegylated liposomal doxorubicin and gemcitabine in platinum-refractory and resistant ovarian cancer following previous platinum-taxane therapy

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 266 KB

Combined PEG liposomal doxorubicin and g

Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum–taxane therapy: A phase II Austrian AGO study

✍ E. Petru; L. Angleitner-Boubenizek; A. Reinthaller; M. Deibl; A.G. Zeimet; B. Vo 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 90 KB

8025 Correlation of Topo II alpha expres

8025 Correlation of Topo II alpha expression and amplification with efficacy of pegylated liposomal doxorubicin in a GEICO phase II trial for platinum-resistant (PR) recurrent ovarian carcinoma (ROC)

✍ Gonzalez-Martin, A.; Casado, A.; Blanco-Sanchez, I.; Bover, I.; Herrero, A.; San 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB